Aaron Gardner represents pharmaceutical, biotechnology, consumer nutrition and medical device companies and private equity investors in a broad range of transactions, including mergers and acquisitions, licenses and collaborations, product divestitures, option transactions, carve-outs, joint ventures and strategic alliances. Mr. Gardner has extensive experience structuring and negotiating complex intellectual property-driven transactions for life sciences companies, including research and development collaborations, platform technology transactions, co-commercialization and co-promotion arrangements, companion diagnostic development agreements and manufacturing and supply arrangements. These transactions cover the full span of the product life cycle, across therapeutic areas and modalities, and frequently involve the cutting-edge technologies that are rapidly changing the face of medicine.

Mr. Gardner previously served as senior M&A counsel for a global biopharmaceutical company. As a result of his tenure as in-house counsel for the client, Mr. Gardner has a real-world understanding of the in-house corporate legal function, and substantial experience counseling corporate executives on a variety of legal and commercial issues.

Experience

  • Novartis in numerous transactions, including: the Series B financing and exclusive option to acquire Kedalion Therapeutics; the divestiture of its rights to dementia treatment Exelon® in Canada and Latin America to Knight Therapeutics; the sale of the Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA (terminated); the sale to Recordati of worldwide rights to Signifor®, Signifor® LAR® and osilodrostat; the sale to Mylan of its global cystic fibrosis products, including the TOBI® Podhaler and TOBI® solution; the sale of the rights to schizophrenia drug Clozaril® in the US and Canada to HLS Therapeutics; the acquisition of Admune Therapeutics, a clinical-stage company with an IL-15 agonist program for metastatic cancer; the 2010 acquisition of the remaining 23% stake in eye-care firm Alcon; the divestiture of a portfolio of ophthalmic products including branded pharmaceuticals, generics, diagnostics and over-the-counter medicines to Laboratoires Thea; the sale to Bausch + Lomb of worldwide rights to Miochol®-E, an injectable miotic; the acquisition by the Sandoz division of Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD; and the acquisition of Corthera, a clinical-stage pharmaceutical company developing relaxin for treatment of acute decompensated heart failure.
  • Pfizer in various transactions, including: the sale to Biogen of a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases; the sale to Biogen of a first-in-class, Phase 2b ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia; and the acquisition of InnoPharma, a privately held sterile product development company focused on developing complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms.
  • Pharmacosmos A/S in the acquisition of Abfero Pharmaceuticals, a clinical-stage pharmaceutical company dedicated to treating diseases of iron overload.
  • Enzyvant in the sale to Aceragen of an investigational enzyme replacement therapy to treat Farber Disease, a group of inherited metabolic disorders for which no disease-specific therapy exists.
  • Alcon in its $285 million acquisition of PowerVision, a medical device development company focused on creating fluid-based intraocular lens implants.
  • Several global pharmaceutical companies in their respective acquisitions of FDA priority review vouchers.
  • Reckitt Bensicker, in the acquisition of UpSpring, an innovative pre- and post-natal healthcare company.
  • Pharmachem Laboratories, a leading provider of quality ingredients to the global health and wellness industries, on its sale to Ashland, a global leader in providing specialty chemical solutions to consumer and industrial markets.
  • Lonza, a Switzerland-based pharmaceutical, biotech and specialty ingredients supplier, in the strategic acquisition of California-based InterHealth Nutraceuticals, a portfolio company of Kainos Capital.
  • Celgene in an equity investment in, development collaboration with, and option to acquire, Abide Therapeutics, a development stage company focused on developing innovative medicines targeting serine hydrolases.

Perspectives

Life Science Transactions: Getting to a Successful Deal
Arnold & Porter Seminar, Cambridge, MA
Life Sciences Transactions Boot Camp
Arnold & Porter Kaye Scholer, Morristown, NJ
Managing Corruption Risks in Life Sciences and Healthcare M&A
Arnold & Porter Kaye Scholer Webinar

Recognition

LMG Life Sciences Guide
"Life Sciences Star" – Mergers & Acquisitions (2018-2021)
"Life Sciences Star" – Licensing & Collaboration (2019-2020)
"Life Sciences Star" – Corporate (2019)
The Deal Awards Middle Market
"Healthcare & Pharma Deal of the Year" (2019)
Law360
Life Sciences "Rising Star" (2016)

Credentials

Education
  • JD, Brooklyn Law School, 2005
  • BS BA, Ohio State University, 2002, cum laude
Admissions
  • New York
  • New Jersey
Overview

Email Disclaimer